Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Study design. AML, acute myeloid leukemia; ET, essential thrombocythemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; RT-qPCR, reverse transcription-quantitative PCR; SPAG6, sperm-associated antigen 6; WB, western blotting.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Quantitative RT-PCR, Real-time Polymerase Chain Reaction, Western Blot

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Relative expression levels and immunoreactivity H-score of SPAG6. (A) SPAG6 mRNA expression in (a) PV, ET, PMF and healthy control groups, and (b) MPN, MDS, AML and healthy control groups. (B) H-score of SPAG6 immunoreactivity in PV, ET, PMF and healthy control groups. ***P<0.01. AML, acute myeloid leukemia; ET, essential thrombocythemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; SPAG6, sperm-associated antigen 6.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Expressing

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Representative immunohistochemical findings in all myeloproliferative neoplasm groups. Immunohistochemical analysis of sperm-associated antigen 6 expression was performed using paraffin-embedded bone marrow biopsy specimens. ET (upper panels), PV (middle panels) and PMF (lower panels). Negative control (left panels), low expression (center panels) and high expression (right panels). Magnification, ×400. ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Immunohistochemical staining, Expressing, Negative Control

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Cell populations expressing SPAG6 in patients with myeloproliferative neoplasms. Sections were stained using H&E staining (left panels) and SPAG6 IHC staining (right panels). Original magnification, ×1,000. The arrows point to the cell types indicated on the left. @, osteocyte; #, osteoblast; and &, osteogenic. IHC, immunohistochemistry; SPAG6, sperm-associated antigen 6.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Expressing, Staining, Immunohistochemistry

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Subcellular localization patterns of SPAG6 protein in patients with myeloproliferative neoplasms. (A) Subcellular localization pattern of SPAG6 protein in the same patient. Immunohistochemical staining (upper panel) and immunofluorescence staining (lower panel) of SPAG6. (B) Subcellular localization pattern of SPAG6 protein in the same cell type. Nucleated erythroid precursors (upper two rows of panels; inside the red circles) and megakaryocytes (lower two rows of panels). Magnification, ×1,000. @, nucleic localization; *, cytoplasmic localization; #, nucleic and cytoplasmic localization; and &, megakaryocyte. SPAG6, sperm-associated antigen 6.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Immunohistochemical staining, Staining, Immunofluorescence

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Double immunofluorescence staining of SPAG6 and β-tubulin expression in bone marrow biopsy specimens from patients with myeloproliferative neoplasms. ET (upper panels), PV (middle panels) and PMF (lower panels). Green fluorescence represents SPAG6 staining and red fluorescence represents β-tubulin staining. Blue staining is DAPI nuclear stain. Merged images (right panels; DAPI + SPAG6 + β-tubulin). Original magnification, ×1,000. ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera; SPAG6, sperm-associated antigen 6.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Double Immunofluorescence Staining, Expressing, Fluorescence, Staining

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Association between SPAG6 expression and clinical characteristics of patients with myeloproliferative neoplasms.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Expressing, Mutagenesis

Journal: Oncology Letters

Article Title: Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms

doi: 10.3892/ol.2021.13128

Figure Lengend Snippet: Receiver operating characteristic curve analysis of SPAG6 expression for distinguishing patients with MPNs from healthy controls, based on the H-score of SPAG6 immunoreactivity. (A) All patients with MPNs (95% CI, 0.8710-0.9556; sensitivity, 81.98%; specificity, 95.65%). Patients with (B) PV (95% CI, 0.8618-0.9815; sensitivity, 83.33%; specificity, 95.65%), (C) ET (95% CI, 0.8827-0.9729; sensitivity, 82.80%; specificity, 100.00%) and (D) PMF (95% CI, 0.7605-0.9533; sensitivity, 67.74%; specificity, 81.43%). AUC, area under the curve; ET, essential thrombocythemia; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; PV, polycythemia vera; SPAG6, sperm-associated antigen 6.

Article Snippet: Following these incubations, the slides were incubated with a rabbit anti-SPAG6 antibody (dilution, 1:400; cat. no. Bs-12291R; BIOSS) overnight at 4°C.

Techniques: Expressing